Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 28, 2014 (12 years ago)

Oxycodone and Acetaminophen Tablets USP 10 mg/325 mg 100 count…

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Content Uniformity Specifications - The lot failed to meet the acceptance criteria for Uniformity of Dosage Units at the time of release for the oxycodone component.

Cause type: Wrong potency / content

Sub- or super-potent product, or a failed content-uniformity / assay test. You may receive too little or too much active ingredient - a direct dosing risk. All wrong potency / content recalls.

What was recalled

Oxycodone and Acetaminophen Tablets USP 10 mg/325 mg 100 count bottles Rx Only. Manufactured by Norwich Pharmaceuticals Inc., Norwich, NY 13185 USA; Distributed by Alvogen Inc, Pine Brook NJ 07058 USA.

Drug: Acetaminophen Category: Pain Relief & OTC Medication

Recalling firm
Alvogen, Inc
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1607-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Acetaminophen recalls

See all
Class II · Moderate risk

Tylenol

Defective Container

Ongoing Packaging defect Kenvue Brands LLC D-0121-2026
Class II · Moderate risk

Acetaminophen 500mg Caffeine 65mg caplets

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The inner pouch correctly states the ingredients are Aspirin (NSAID)*500mg and Caffeine 32.5mg.

Ongoing Labeling / mix-up Aero Healthcare NDC 55305-135-01 D-0155-2026

Other recalls by Alvogen, Inc

All 2014 recalls
Class II · Moderate risk

Levothyroxine Sodium Tablets

Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

Ongoing Labeling / mix-up Alvogen, Inc D-0259-2026
Class I · High risk

Fentanyl Transdermal System CII

Defective delivery system - patches could be multi-stacked, adhered one on top of the other, in a single product pouch.

Ongoing Packaging defect Alvogen, Inc NDC 47781-424-47 D-0245-2025